The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3425-3429

  Gavrilov, Vladimir ^a   Steiner, Michael ^a   Shany, Shraga ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Ibuprofen; LNCaP cells; NSAID; Prostate cancer; Vitamin D

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CALCITRIOL; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROPIDIUM IODIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; STATISTICAL ANALYSIS; STUDENT T TEST;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; HUMANS; IBUPROFEN; MALE; PROSTATIC NEOPLASMS;

EID: 23344449304     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Holick MF: Vitamin D and bone health. J Nutr 126: 1159S-1164S, 1996.
2. Reichel H, Koeffler KA and Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989.
3. Walters MR: Newly identified actions of the vitamin D endocrine system. Endocr Rev 13: 719-764, 1992.
4. 3 in growth regulation of cancer cell lines. Anticancer Res 18: 1769-1776, 1998.
5. Schwartz GG and Hulka BS: Is Vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1312, 1990.
6. Shany S, Chaimovitz C, Yagev R, Bercovich M and Lowenhtal MN: Vitamin D deficient elderly: Treatment with ergocalciferol and hydroxylated analogues of vitamin D3. Isr J Med Sci 24: 160-163, 1988.
7. Need AG, Morris HA, Horowitz M and Nordin BEC: Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr 58: 882-885, 1993.
8. 3. J Clin Invest 76: 1536-1538, 1985.
9. Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94: 1867-1875, 2002.
10. Grant WB: Ecologic studies of solar UV-B radiation and cancer mortality rates. Rec Results Cancer Res 164: 371-377, 2003.
11. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH and Orentreich N: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev 2: 467-472, 1993.
12. Ahonen MH, Tenkanen L, Teppo L, Hakama M and Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847-852, 2000.
13. 3-induced growth inhibition. Cancer Res 61: 2852-2856, 2001.
14. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF and Chen TC: 25-Hydroxyvitamin D- 1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81: 135-140, 2002.
15. Chen TC, Wang L, Whitlatch LW, Flanagan JN and Holick MF: Prostatic 25-Hydroxyvitamin D-1α-hydroxylase and its application in prostate cancer. J Cell Biochem 88: 315-322, 2003.
16. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW and Trump DL: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345, 1999.
17. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA and Henner WD: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21: 123-129, 2003.
18. DuBois RN, Giardiello FM and Smalley WE: Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 25: 773-791, 1996.
19. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A and Baron JA: Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88: 1687-1692, 2003.
20. Nelson JE and Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169-170, 2000.
21. Andrews J, Djakiew D, Krygier S and Andrews P: Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 50: 277-284, 2002.
22. Davies NM: Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34: 101-154, 1998.
23. 3. Leuk Res 22: 153-161, 1998.
24. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138: 3290-3298, 1997.
25. Andrews P, Krygier S and Djakiew D: Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells. Cancer Chemother Pharmacol 49: 179-186, 2002.
26. Esquenet M, Swinnen JV, Heyns W and Verhoeven G: Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28: 182-194, 1996.
27. Bao BY, Hu YC, Ting HJ and Lee YF: Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 23: 3350-3360, 2004.
28. Lou YR, Nazarova N, Talonpoika R and Tuohimaa P: 5alpha- dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D(3)-induced expression of CYP24 in human prostate cancer cells. Prostate. Published Online: 10 Nov 2004. DOI: 10.1002/pros.20189.
29. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase-2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998.
30. 3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61: 7122-7129, 2001.